Ticker

No recent analyst price targets found for BGMS.

Latest News for BGMS

EQUITY ALERT: The M&A Class Action Firm Launches Inquiry for the Merger— ATKR, BGMS, BOW and FTHM

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

GlobeNewsWire • Sep 8, 2026
Financial Review: Peak Pharmaceuticals (OTCMKTS:PKPH) versus Cyclacel Pharmaceuticals (NASDAQ:BGMS)

Cyclacel Pharmaceuticals (NASDAQ: BGMS - Get Free Report) and Peak Pharmaceuticals (OTCMKTS:PKPH - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings. Profitability This table compares Cyclacel…

Defense World • Jul 26, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for BGMS.

No House trades found for BGMS.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top